首页 | 官方网站   微博 | 高级检索  
     

高血糖素及其受体研究进展
引用本文:任彦荣.高血糖素及其受体研究进展[J].中国药业,2007,16(19):1-2.
作者姓名:任彦荣
作者单位:重庆教育学院生化系,重庆,400067
摘    要:在治疗2型糖尿病的药物中,西药见效快但有副作用,如磺脲类药物会引起体重增加;中药注重整体调节,但起效慢。因此,研制快速起效且安全可靠的药物是治疗2型糖尿病的关键。高血糖素是胰岛α细胞分泌的多肽激素,主要作用于肝脏,可促进肝糖原分解,抑制肝糖原合成,促进葡萄糖异生、分解,其受体拮抗剂可能是治疗2型糖尿病的有效药物。该文就高血糖素及其受体的研究进展作一论述。

关 键 词:2型糖尿病  高血糖素  高血糖素受体  进展
文章编号:1006-4931(2007)19-0001-02
修稿时间:2007-05-08

Progress of Studies on Glucagon and Glucagon Receptor
Ren Yanrong.Progress of Studies on Glucagon and Glucagon Receptor[J].China Pharmaceuticals,2007,16(19):1-2.
Authors:Ren Yanrong
Affiliation:Department of Life Science and Chemistry, Chongqing Education College, Chongqing, China 400067
Abstract:Among the medicine treating type 2 diabetes, the Western medicine is effective, but has adverse reactions, such as biguanides could cause body weight gain; the traditional Chinese medicine is concept of wholism,but is less sensitive. So it is significant to develop effective and safe drug treating type 2 diabetes. Glucagon is a kind of peptide hormones sercreted by pancreatic island α- cell, which accelerates glycogenolysis and gluconeogenesis and restrains glycogenesis. The receptor blocker of glucagon is conceivably effective on treating type 2 diabetes mellitus. The progress of research on glucagon and glucagon receptor is discussed.
Keywords:type 2 diabetes  glucagon  glucagon receptor  progress
本文献已被 CNKI 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司    京ICP备09084417号-23

京公网安备 11010802026262号